Evotec Signs an Agreement with Celmatix to Develop Pre-Clinical Candidates for Women Health

 Evotec Signs an Agreement with Celmatix to Develop Pre-Clinical Candidates for Women Health

Nosopharm Signs an Agreement with Evotec to Accelerate the Development of Antibiotics

Shots:

  • Evotec will take care of medicinal chemistry, in vitro and in vivo pharmacology plus its development capabilities and expertise while Celmatix will utilize its novel drug target discovery based on its multi-omics Reproductive Atlas platform
  • The focus of the agreement is to combine Celmatix database and expertise with Evotec’s footprints in therapeutic discovery with the focus of developing pre-clinical candidates for women’s reproductive health, including polycystic ovary syndrome (“PCOS”), endometriosis, and infertility
  • Celamtix’s Reproductive Atlas platform is a database enabled with biological annotations refined from the peer-reviewed literature with genomic data linked to data about lifestyle, diet, environment, and reproductive outcomes and has launched its first study with the BioMe BioBank Program of the Charles Bronfman Institute for Personalized Medicine

Click here to­ read full press release/ article | Ref: Evotec | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post